NewsRoom Articles - Page 71 of 154 - PsychedelicNewsWire (PNW)

ThursdayJan 27, 2022 12:18 pm

Pennsylvania May Legalize Psychedelics Faster Than It Did Cannabis

Recently, Pennsylvania state Reps Jennifer O’Mara and Tracy Pennycuick introduced the Public Health Benefits of Psilocybin Act to the House. The measure, dubbed House Bill 1959, will allow studies to be conducted on the use of psilocybin as a treatment of various mental health conditions, from substance-abuse and eating disorders to suicidal ideation and post-traumatic stress disorder, in the state. The measure notes that priority will be given to studies with retired first responders and veterans. Bradford Bitting, husband to O’Mara, has served two combat tours in Afghanistan, which earned him two Purple Hearts. Bitting suffers from post-traumatic stress disorder.…

ThursdayJan 27, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health treatment” Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process A USA Today article is touting psychedelics as the next big thing in mental health treatment (https://ibn.fm/3ZGGE). This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE American: CYBN) has been working toward since the company started: a strategic psychedelics to therapeutics model that will transform the mental health space. “If you haven't heard about psychedelics being used as a treatment…

WednesdayJan 26, 2022 11:47 am

Study Shows That Ketamine May Effectively Treat Alcohol Use Disorder

Awakn Life Sciences recently announced results from its double-blind, placebo-controlled trial, which is exploring the effectiveness of ketamine-assisted therapy in treating alcohol use disorder. The results show promise, offering hope for millions of individuals around the globe who suffer from alcohol addiction. The trial comprised of 96 patients suffering from severe alcohol use disorder who were randomly divided into four groups. The first group received three ketamine IV infusions and proprietary, manualized therapy. The second group received proprietary, manualized therapy and the placebo, which was three saline infusions. The third group received alcohol education and ketamine infusions, while the fourth…

TuesdayJan 25, 2022 1:58 pm

New Measures Filed in Virginia Could Decriminalize Psychedelics

Last week, legislators in the state of Virginia introduced new measures to decriminalize the possession of psychedelic substances. The bills in the Senate and the House of Delegates are almost identical, except that the proposal in the latter covers a number of psychedelic substances while the first one only calls for a reduction in the penalties imposed for psilocin and psilocybin possession. The measure introduced in the House would amend the Virginia’s drug statute by making the possession of psilocin, psilocybin, ibogaine or peyote by individuals aged 21 and above a civil penalty punishable by a $100 fine. The possession…

TuesdayJan 25, 2022 12:21 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Reports Findings of Commissioned Study Showing a Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment for Select Mental Conditions

The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies…

MondayJan 24, 2022 12:29 pm

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices

Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapy The products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support The planned launch follows an amendment to federal regulations allowing physicians to request and prescribe restricted drugs for treatment-resistant patients Canada began the year on a high note by updating the Special Access Program (“SAP”), a move that demonstrates the government’s serious consideration of the…

MondayJan 24, 2022 10:49 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to Launch Specialized Psychedelic Program in Canada

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) announced that it would be launching a special access psychedelic-assisted psychotherapy program, called the Special Access Support and Supply Program. The program will be available to patients who require alternative treatment modalities in Canada. The country recently added psilocybin and MDMA to its Special Access Program. Mydecine’s objective is to change the way in which mental health conditions and addiction disorders are treated. The company will provide support services through the program, which will play an important role in fulfilling the company’s mission statement. This is in addition to offering specialized psychedelic…

FridayJan 21, 2022 10:38 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Corporate Update Points to Profitability in 2022 and Beyond

In 2021, Delic’s investments and acquisitions allowed for an annualized revenue run-rate of over $9MM Going into the new year, the company looks forward to opening additional ketamine infusion treatment clinics, growing them by 15 within the next 18 months Delic’s growth has been attributed to the strong demand for alternatives to current treatments for mental health conditions Its management is confident that the foundations laid down so far position Delic for growth and profitability in 2022 and beyond 2021 was an excellent year for Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), as indicated in the company’s recent update…

FridayJan 21, 2022 10:35 am

Ancient Latin American Empire Could Have Thrived Thanks to Psychedelic-Infused Beer

A new study has found that the leaders of Wari may have laced their beer with hallucinogens to keep their political control for centuries. The drugs are said to have been extracted from plant seeds. The Wari are a South American civilization that ruled the highlands of what is now known as Peru, before the Incas. The culture occupied the highlands between 600 AD and 1000 AD. Archaeological excavations that were conducted between 2013 and 2017 at the Quilcapampa site in the south of Peru have discovered that the tribe used seeds derived from the vilca tree then combined the…

ThursdayJan 20, 2022 10:03 am

Study Finds That Sleep Deprivation Increases Serotonin 2AReceptor Levels in Brain

A new study conducted by researchers at the University of Arizona Health Sciences has found that sleep deprivation can cause a significant increase in serotonin 2A levels in a matter of hours in animal models.Serotonin 2A, or the 5-HT2A receptor, plays a crucial role in cognition, perception and psychosis. The receptor is extensively distributed in the brain and is responsible for the psychedelic effect of substances such as LSD and psilocybin. Abnormal function of 5-HT2A receptors has been linked to psychiatric disorders, including schizophrenia, which explains why antipsychotic medications prescribed for the treatment of schizophrenia have been designed to target…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000